A decoquinate hapten, antigen, antibody and preparation and application thereof

By preparing water-soluble enhanced decioxoquine haptens and corresponding monoclonal antibodies, the problem of anticoccidial drug residue detection in complex matrix is ​​solved, and high sensitivity and specific detection of decioxoquine is achieved.

CN118724807BActive Publication Date: 2024-11-15GUANGZHOU VOCATIONAL COLLEGE OF TECH & BUSINESS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411207661.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-11-15
Estimated Expiration
2044-08-30

AI Technical Summary

Technical Problem

The prior art is difficult to effectively detect anticoccidial drug residues in complex matrixes such as liver and kidneys. Especially due to the high lipid solubility and poor solubility of the drug, it leads to difficulty in designing hapten and antibody preparation, and lacks the ability to specifically recognize decyloxyquine. Monoclonal antibodies.

Method used

By attaching the deoxoquine analog with strong water-soluble arms, an increased polar deoxoquine hapten was prepared, and corresponding monoclonal antibodies were prepared, and immune detection was achieved using antigen-antibody specific recognition.

Benefits of technology

Monoclonal antibodies with good specificity and sensitivity to decanoquine were obtained, with IC50 value of 12.3 ng/mL, detection limit LOD of 3.41 ng/mL, linear range of 7.4~20.9 ng/mL, effectively excluding other structures The interference of analogs provides the core reagent of the immunoassay method of decioxoquine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118724807B_ABST
    Figure CN118724807B_ABST
Patent Text Reader

Abstract

The present invention discloses a decoquinate hapten, antigen, antibody and their preparation and application, and relates to a decoquinate hapten, antigen, antibody and their preparation and application for detecting decoquinate residues. The present invention prepares a decoquinate hapten and an artificial antigen with a structural formula as shown in formula (I) by using a highly water-soluble arm, and further prepares a specific antibody for detecting decoquinate, and the half inhibition concentration IC of decoquinate is 50 The value was 12.3 ng / mL, and the detection limit LOD (IC 10 ) was 3.41 ng / mL, and the linear range (IC 20 ~IC 80 ) was 7.4~20.9ng / mL, and the cross-reaction rates to common structural analogs were all lower than 10%, indicating that the antibody had good specificity for decoquinate and could effectively eliminate the interference of other structural analog drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of food safety detection, and more specifically, to a decoquinate hapten, antigen, antibody and preparation and application thereof. Background Art

[0002] Decoquinate is a quinoline anticoccidial drug. Among the anticoccidial drugs, quinoline anticoccidial drugs were developed earlier and have better efficacy. To date, several drugs are still added to feed to prevent and treat coccidiosis. Although this type of anticoccidial drug has low toxicity, the use of anticoccidial drugs can easily lead to drug resistance in coccidia, and there is a tendency to increase the dosage of anticoccidial drugs used in livestock production.

[0003] In recent years, liquid chromatography-tandem mass spectrometry has become one of the main methods for detecting veterinary drug residues. There are also many reports on the use of liquid chromatography-tandem mass spectrometry to determine anticoccidial drug residues, mainly for chicken, eggs, and beef. There are also reports on the detection of anticoccidial drug residues in chicken skin and fat, chicken excrement, etc. However, there are few studies on the detection of anticoccidial drug residues in complex matrices such as liver and kidney.

[0004] The immunoassay method based on antigen-antibody specific recognition is one of the main technologies for veterinary drug residue detection. However, due to the high lipid solubility and poor solubility of such drugs, the difficulty in hapten design and antibody preparation, there are currently no relevant reports. Therefore, there is an urgent need for monoclonal antibodies that can specifically recognize decoquinate to lay the foundation for the development of rapid immune detection technology and products for decoquinate. Summary of the invention

[0005] The purpose of the present invention is to use a highly water-soluble arm to connect to a decoquinate analogue to obtain a decoquinate hapten with increased polarity and enhanced water solubility, thereby enhancing the immune effect of the antigen.

[0006] According to one aspect of the present invention, a decoquinate hapten is provided, the structure of which is shown in formula (I):

[0007] , formula (Ⅰ).

[0008] According to another aspect of the present invention, there is provided a method for preparing decoquinate hapten, comprising the following steps:

[0009] S1. 4-aminophenol and diethyl ethoxymethylenemalonate were dissolved in isopropanol, reacted at room temperature under alkaline conditions, insoluble matter was removed by filtration, and the solvent was evaporated to obtain intermediate 1. Intermediate 1 was dissolved in diphenyl ether, reacted at 250°C for 30 minutes, cooled to room temperature, the product precipitated, and washed with n-hexane to obtain intermediate 2. The reaction formula of this step is shown in the following formula (II):

[0010] , formula (II);

[0011] S2. The intermediate 2 is dissolved in DMF, and tert-butyl bromide and potassium carbonate are added, wherein the molar ratio of the intermediate 2, tert-butyl bromide and potassium carbonate is 1:1:1. The temperature is raised to 90°C and reacted overnight. A large amount of saturated brine is added, and the mixture is extracted with ethyl acetate. After the organic layer is evaporated to dryness, the mixture is subjected to column chromatography to obtain the intermediate 3. The reaction formula of this step is shown in the following formula (III):

[0012] , formula (III);

[0013] S3. The intermediate 3 is dissolved in dichloromethane and reacted with trifluoroacetic acid. After the reaction is completed, the solvent is evaporated to obtain a decoquinate hapten, whose structural formula is shown in formula (I). The reaction formula of this step is shown in formula (IV) below.

[0014] , formula (IV).

[0015] In some embodiments, in step S1, the molar ratio of 4-aminophenol to diethyl ethoxymethylenemalonate is 1:(1-1.2), and the alkaline condition is to add potassium carbonate or sodium carbonate into the reaction system.

[0016] According to another aspect of the present invention, a decoquinate antigen is provided, which is a conjugate of decoquinate hapten and a carrier protein.

[0017] In some embodiments, the carrier protein is bovine serum albumin, human serum albumin, chicken ovalbumin, or hemocyanin.

[0018] According to a fourth aspect of the present invention, a decoquinate antibody is provided. The decoquinate antibody is prepared by immunizing an animal with a decoquinate antigen. The decoquinate antibody is a decoquinate monoclonal antibody.

[0019] According to a fifth aspect of the present invention, there is provided the use of decoquinate hapten and decoquinate antigen in immunological detection of decoquinate for non-disease diagnosis purposes.

[0020] According to a sixth aspect of the present invention, there is provided use of a decoquinate antibody in immunological detection of decoquinate for non-disease diagnosis purposes.

[0021] According to a seventh aspect of the present invention, a method for detecting decoquinate for non-disease diagnosis purposes is provided, wherein the method uses decoquinate antigens and decoquinate antibodies to detect decoquinate drug residues in food, wherein the food is animal-derived food.

[0022] Beneficial effects of the present invention: The present invention prepares the decoquinate hapten and artificial antigen with the structural formula shown in formula (I) by using a highly water-soluble arm, and further prepares a specific antibody for detecting decoquinate, and the half inhibitory concentration IC of decoquinate is 50 The value was 12.3 ng / mL, and the detection limit LOD (IC 10 ) was 3.41 ng / mL, and the linear range (IC 20 ~IC 80 ) was 7.4~20.9ng / mL, and the cross-reaction rates to common structural analogs were all lower than 10%, indicating that the antibody had good specificity for decoquinate and could effectively eliminate the interference of other structural analog drugs, providing a core reagent for establishing the immunoassay method of decoquinate. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 The mass spectrum of decoquinate hapten according to one embodiment of the present invention.

[0024] Figure 2 The standard curve of the indirect competitive ELISA established based on the decoquinate monoclonal antibody according to one embodiment of the present invention is shown in FIG. DETAILED DESCRIPTION

[0025] The present invention is further described in detail through specific implementation cases, and it should be understood that these embodiments are only used to illustrate the present invention and are not used to limit the scope of protection of the present invention. After reading the present invention, the modifications of various equivalent forms of the present invention by those skilled in the art are all limited by the claims attached to this application. Unless otherwise specified, all raw materials and reagents of the present invention are raw materials and reagents that can be purchased in the conventional market.

[0026] Example 1 Preparation of decoquinate hapten

[0027] The preparation method of decoquinate hapten comprises the following steps:

[0028] S1. Weigh 4.36 g of 4-aminophenol, 9.0 g of diethyl ethoxymethylenemalonate, and 6.5 g of potassium carbonate respectively and dissolve them in 50 mL of isopropanol. React at room temperature overnight. Filter after the reaction and evaporate the filtrate to dryness to obtain intermediate 1 (subsequent experiments can be directly carried out without purification). Dissolve intermediate 1 in 40 mL of diphenyl ether and react at 250 °C for 30 min for cyclization reaction. Cool to room temperature to precipitate the product, wash with n-hexane, and recrystallize to obtain 6.25 g of intermediate 2 with a total yield of 67%;

[0029] S2. Dissolve 2.4 g of intermediate 2 in 30 mL of DMF, add 2.6 g of tert-butyl bromotriethylene glycol acetate and 2.5 g of potassium carbonate, heat to 90 °C and react overnight. After the reaction, add a large amount of saturated brine, extract with 50 mL of ethyl acetate 2-3 times, evaporate the organic layer with anhydrous sodium sulfate, and pass column chromatography to obtain 3.2 g of intermediate 3;

[0030] S3. Dissolve 1.5 g of intermediate 3 in 10 mL of dichloromethane and then slowly add 5 mL of trifluoroacetic acid to react for 30 min. After the reaction is completed, evaporate the solvent, add saturated brine to wash, extract with 30 mL of ethyl acetate 2-3 times, and evaporate the organic layer with anhydrous sodium sulfate to obtain the decoquinate hapten.

[0031] The decoquinate hapten was identified by mass spectrometry, and the mass spectrum obtained is shown in Figure 1 .from Figure 1 It can be seen that the molecular ion peak of decoquinate hapten is ESI- [MH] - : 422.26, which is the highest peak, consistent with the molecular weight of the decoquinate hapten 423.42, indicating that the decoquinate hapten shown in formula (I) was successfully synthesized.

[0032] Example 2 Preparation of Decoquinate Immunization Antigen and Coating Antigen

[0033] 2.1 Preparation of antigen for decoquinate immunization

[0034] The decoquinate hapten prepared in Example 1 was used to couple lactoferrin (LF) by the active ester method to prepare the decoquinate immunization antigen, and the specific method is as follows:

[0035] 16.5 mg of the decoquinate hapten prepared in Example 1 was dissolved in 0.5 mL of DMF solution, 12 mg of EDC.HCl and 10 mg of NHS were added with stirring, and the mixture was reacted overnight at room temperature in the dark to obtain a decoquinate hapten activation solution; 16 mg of LF was dissolved in 1.6 mL of BB buffer solution with a pH of 9.0, 150 μL of the decoquinate hapten activation solution was added with stirring, and the mixture was evenly mixed and coupled at room temperature in the dark for 4 h to obtain a coupling mixture; the coupling mixture was dialyzed with PBS buffer solution at 4°C for 3 days, and the dialyzate was replaced twice a day to obtain a decoquinate immunization antigen (decoquinate hapten-LF), which was packaged at a concentration of 1 mg / mL and frozen in a -20°C refrigerator.

[0036] 2.2 Preparation of decoquinate coating antigen

[0037] The decoquinate hapten prepared in Example 1 was used to couple bovine serum albumin (BSA) by the active ester method to prepare a decoquinate coating antigen. The specific method is as follows:

[0038] 15.7 mg of the decoquinate hapten prepared in Example 1 was dissolved in 0.5 mL of DMF solution, 12 mg of EDC and 10 mg of NHS were added with stirring, and the mixture was reacted overnight at room temperature in the dark to obtain a decoquinate hapten activation solution; 24 mg of BSA was dissolved in 2.4 mL of BB buffer solution with a pH of 9.0, 225 μL of the decoquinate hapten activation solution was added with stirring, and the mixture was evenly stirred and coupled at room temperature in the dark for 4 h to obtain a coupling mixture; the coupling mixture was dialyzed with PBS buffer solution at 4°C for 3 days, and the dialyzate was replaced twice a day. The decoquinate coating antigen (decoquinate hapten-BSA) obtained was packaged at a concentration of 1 mg / mL and frozen in a -20°C refrigerator.

[0039] Example 3 Preparation and identification of decoquinate monoclonal antibodies

[0040] 3.1 Immunization of mice

[0041] Take 250 μL of the decoquinate immunization antigen (decoquinate hapten-LF) prepared in Example 2 and diluted to 1 mg / mL and emulsify it evenly with an equal amount of immune adjuvant (Freund's complete adjuvant for the first immunization, and Freund's incomplete adjuvant for subsequent booster immunizations) to immunize animals; 6-7 week-old Bal b / c mice were immunized by multiple injections of subcutaneous dorsal, subcutaneous, abdominal and foot injections, with an immunization dosage of 100 μL / mouse. After 2 weeks, the second immunization was performed, and booster immunization was performed every 2 weeks thereafter. Blood was collected from the tail of the mice 1 week after the third booster immunization, and the serum titer was determined by indirect competitive ELISA. When the titer no longer rises, 100 μL of 1 mg / mL decoquinate immunization antigen was injected intraperitoneally for impact immunization;

[0042] 3.2 Cell fusion

[0043] Three days after the shock immunization, PEG (polyethylene glycol) was used for cell fusion. The specific steps are as follows:

[0044] a. Collect mouse spleen cells: kill the mice by cervical dislocation, and immediately soak them in 75% alcohol to sterilize. Take out the spleen of the mice aseptically and put it into a 200-mesh cell sieve. Grind it moderately with the rubber tip of a sterile syringe, and rinse it with basal culture medium to obtain a spleen cell suspension. Collect it, centrifuge it (1000 rpm, 7 min), and wash the spleen cells three times with basal culture medium. After the last centrifugation, dilute the spleen cells to a certain volume, count them, and set aside.

[0045] b. Collect SP2 / 0 cells: 7-10 days before fusion, culture SP2 / 0 myeloma cells with complete medium in a 5% CO2 incubator. Before fusion, the number of SP2 / 0 tumor cells should reach 1-4×10 7 , to ensure that SP2 / 0 tumor cells are in the logarithmic growth phase before fusion. During fusion, myeloma cells are collected, suspended in basal culture medium, and cell counts are performed;

[0046] c. Mix the two cells in a ratio of spleen cells: SP2 / 0 = 5:1, centrifuge, discard the supernatant, and obtain the mixed cells deposited at the bottom of the centrifuge tube;

[0047] d. Fusion: In the first minute, slowly add 1 mL of PEG to the cells at the bottom of the centrifuge tube; in the second minute, keep the centrifuge tube shaking at a constant speed; in the third minute, add 1 mL of preheated basal medium; in the fourth minute, add 3 mL of preheated basal medium; in the fifth minute, add 8 mL of preheated basal medium; in the sixth minute, add 8 mL of preheated basal medium; centrifuge (1000 rpm, 7 min), discard the supernatant, resuspend in HAT screening culture medium, add 200 μL / well to a 96-well cell plate, and culture in a 37°C, 5% CO2 incubator;

[0048] 3.3 Cell screening and cell line establishment

[0049] On the 5th day of cell fusion, half of the fusion cells were replaced with HT medium, and the whole medium was replaced on the 8th day. On the 10th day, the cell supernatant was taken and screened by ic-ELISA, and the inhibitory effect of positive cells was determined. The cell wells with good inhibition of the decoquinate standard were selected, subcloned by limiting dilution method, and tested by the same method, repeated 4 to 5 times to obtain cell lines;

[0050] 3.4 Preparation and identification of monoclonal antibodies

[0051] Several Bal b / c mice aged 10 weeks or older were selected and each mouse was intraperitoneally injected with 500 μL of liquid paraffin. Seven days later, each mouse was intraperitoneally injected with approximately 1×10 6 Hybridoma cells, after another 7 days, the abdomen of the mouse swells and ascites is collected, and the collected ascites is purified by chromatography. 1 mL of protein G filler is used to pack the column, and 50 mL of ascites diluted with PBS buffer is added. The flow-through liquid is repeatedly loaded 7 to 8 times, and then eluted with glycine, and the eluate is adjusted to neutrality in time with Tris-HCl. Dialysis desalting is performed, and finally the purified decoquinate monoclonal antibody A4B1 is obtained, which is stored at -20 ℃ after aliquoting.

[0052] Example 4 ELISA performance evaluation of decoquinate monoclonal antibody

[0053] The titer and inhibition rate of the antibody were determined by indirect competitive ELISA. The specific method is as follows:

[0054] (1) Coating: Dilute the coating agent to 1 μg / mL with coating solution, add 100 μL / well, and coat overnight in a 37°C water bath.

[0055] (2) Blocking: discard the coating solution, wash the plate twice, pat dry on absorbent paper, add 120 μL of blocking solution to each well, incubate in a 37 ℃ water bath for 3 h. Shake dry, and dry inverted in a 37 ℃ oven for 1 h;

[0056] (3) Add antibodies and drugs: dilute the monoclonal antibody with PBS to 1K (1000), 2K, 4K, 8K, 16K, 32K, 64K and other multiples; dilute the decoquinate standard with PBS to 100 ng / mL and set aside;

[0057] Titer column: first add 50 μL PBS buffer to each well, then add the diluted monoclonal antibody into each well at 50 μL / well, and add PBS to the last well as a blank control;

[0058] Inhibition column: First, add 50 μL of drug diluted with PBS buffer to each well, then add 50 μL / well of graded diluted antibody to each well, and add PBS to the last well as a blank control;

[0059] Incubate at 37 °C for 40 min and wash the plate five times;

[0060] (4) Add secondary antibody: Add goat anti-mouse secondary antibody diluted 5000 times with PBST buffer (100 μL / well), incubate at 37 °C for 30 min, and wash the plate 5 times;

[0061] (5) Color development: Mix equal volumes of TMB substrate buffer A and B to obtain substrate solution, add substrate solution (100 μL / well), and incubate at 37 °C for 10 min;

[0062] (6) Termination: Add 10% H2SO4 stop solution (50 μL / well) to the ELISA plate to terminate the reaction;

[0063] (7) Reading: Read the absorbance (OD) with an ELISA reader at a wavelength of 450 nm. The antibody dilution multiple with an absorbance value in the range of 1.0 to 1.5 is selected as the antibody titer. The drug recognition performance of the antibody is derived from its inhibition rate. The inhibition rate is calculated as shown in formula (V). The specific titer and inhibition rate results are shown in Table 1.

[0064] , formula (V).

[0065] Table 1 Antiserum titer and inhibition rate

[0066]

[0067] As shown in Table 1, at a drug concentration of 100 ng / mL, the highest titer was 45K, and the inhibition rate was 93.45%. This shows that the serum has high sensitivity and good titer, and the reaction conditions can be further optimized to develop an immunoassay method for decoquinate.

[0068] Example 5 Specificity evaluation of decoquinate monoclonal antibody

[0069] In this example, several analogs with similar structures to decoquinate were selected under the optimized icELISA conditions using the icELISA program to investigate the specificity of the decoquinate monoclonal antibody prepared in Example 3. Decoquinate analog competition inhibition curves were made in turn to find the mass concentration of the standard when the inhibition rate was 50%, and then converted into molar concentrations to calculate the cross-reaction rate between each structural analog and the antibody using a formula, as shown in Table 2 below. Three replicates were set for each treatment.

[0070]

[0071] As shown in Table 2, the decoquinate monoclonal antibody prepared in Example 3 has a high sensitivity to recognize decoquinate, and only has a high cross-recognition rate for butaquinate and trimethoquinate; although other drugs all contain quinoline groups, they also have large differences in side chain groups, so the cross-recognition rate of the decoquinate monoclonal antibody to other structural analogs is less than 10%. It proves that the decoquinate monoclonal antibody prepared in Example 3 has good specificity for decoquinate.

[0072] Example 6

[0073] 6.1 An indirect competitive ELISA method for detecting decoquinate

[0074] (1) The decoquinate coating antigen prepared in Example 2 was diluted to 4 μg / mL with carbonate buffer (CB, 0.1M pH=9.8), coated on a 96-well ELISA plate, 100 μL was added to each well, incubated at 37°C overnight (12 h), the liquid in the wells was poured off, the wells were washed twice with a washing solution, each time for 30 s, and patted dry. Then, 200 μL of blocking solution was added to each well, incubated at 37°C in the dark for 2 h, the liquid in the wells was poured off, patted dry, and after drying, the wells were vacuum sealed with aluminum film for storage;

[0075] (2) Discard the coating solution, wash twice, and pat dry;

[0076] (3) Add 120 μL of blocking solution (i.e., 5% skim milk powder by weight) to each well and block at 37°C for 3 h;

[0077] (4) Discard the blocking solution, clap the plate, dry it at 37°C for 30 min, take it out, and put it in a ziplock bag for later use;

[0078] (5) Dilute the decoquinate monoclonal antibody prepared in Example 3 with phosphate buffer (PBS, 0.01M, pH=7.4) at a ratio of 1:16000, and dilute the decoquinate drug to be tested in a 4-fold gradient to 125 μg / L, 31.25 μg / L, 7.8 μg / L, 1.95 μg / L, 0.49 μg / L, and 0.12 μg / L;

[0079] (6) Add 50 μL of the decoquinate drug dilution to be tested to each row (three parallel groups), then add the decoquinate monoclonal antibody dilution at a ratio of 50 μL / well, incubate at 37°C for 40 min, wash five times, and pat dry;

[0080] (7) Add 5000-fold diluted goat anti-mouse secondary antibody-HRP in phosphate-buffered saline (PBST, 0.01 M), 100 μL / well, incubate at 37°C for 30 min, wash five times, and pat dry;

[0081] (8) Add 100 μL of color developing solution to each well and develop the color for 10 min.

[0082] (9) Add 50 μL of 10% H2SO4 solution to terminate the reaction and read the OD value at 450 nm;

[0083] (10) Follow the above steps (1) to (9), replace the dilution of decoquinate to be tested in step (6) with the dilution of the extracted sample to be tested, and combine with the drawn standard curve to determine the actual decoquinate drug content in the unknown sample.

[0084] 6.2 Test results

[0085] The standard curve of the antibody indirect competition ELISA used to detect decoquinate is shown in the attached figure. Figure 2 As shown, from Figure 2 It can be seen that the detection of decoquinate antibodies is the IC 50 The value was 12.3 ng / mL, and the detection limit LOD (IC 10 ) was 3.41 ng / mL, and the linear range (IC 20 ~IC 80 ) is 7.4~20.9ng / mL, and the cross-over rate to other structural analogs does not exceed 10%, which can be used to establish a high-sensitivity immunoassay method to detect decoquinate.

[0086] The above are only some embodiments of the present invention. For those skilled in the art, several modifications and improvements may be made without departing from the inventive concept of the present invention, which all fall within the protection scope of the present invention.

Claims

1. A decoquinate hapten, characterized in that Its structure is shown in formula (I): , (Ⅰ)。 2. A method for preparing the decoquinate hapten according to claim 1, characterized in that: The following steps are involved: S1. 4-aminophenol and diethyl ethoxymethylenemalonate were dissolved in isopropanol, reacted at room temperature under alkaline conditions, insoluble matter was removed by filtration, and the solvent was evaporated to obtain intermediate 1. Intermediate 1 was dissolved in diphenyl ether, reacted at 250°C for 30 minutes, cooled to room temperature, the product precipitated, and washed with n-hexane to obtain intermediate 2. The reaction formula of this step is shown in the following formula (II): , formula (II); S2. The intermediate 2 is dissolved in DMF, and tert-butyl bromide and potassium carbonate are added, wherein the molar ratio of the intermediate 2, tert-butyl bromide and potassium carbonate is 1:1:

1. The temperature is raised to 90°C and reacted overnight. A large amount of saturated brine is added, and the mixture is extracted with ethyl acetate. After the organic layer is evaporated to dryness, the mixture is subjected to column chromatography to obtain the intermediate 3. The reaction formula of this step is shown in the following formula (III): , formula (III); S3. The intermediate 3 is dissolved in dichloromethane and reacted with trifluoroacetic acid. After the reaction is completed, the solvent is evaporated to obtain the decoquinate hapten, whose structural formula is shown in formula (I). The reaction formula of this step is shown in formula (IV). , formula (IV).

3. The method for preparing decoquinate hapten according to claim 2, characterized in that: In the step S1, the molar ratio of 4-aminophenol to diethyl ethoxymethylenemalonate is 1:(1-1.2), and the alkaline condition is to add potassium carbonate or sodium carbonate into the reaction system.

4. Decoquinate antigen, characterized in that The decoquinate antigen is a conjugate of the decoquinate hapten according to claim 1 and a carrier protein.

5. The decoquinate antigen according to claim 4, characterized in that The carrier protein is bovine serum albumin, human serum albumin, chicken ovalbumin or hemocyanin.

6. Use of the decoquinate hapten according to claim 1 and the decoquinate antigen according to claim 4 in immunological detection of decoquinate for non-disease diagnosis purposes.